This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n9http://linked.opendata.cz/resource/domain/vavai/subjekt/
n8http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00669806%3A_____%2F13%3A10139964%21RIV14-MZ0-00669806/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n16http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00669806%3A_____%2F13%3A10139964%21RIV14-MZ0-00669806
rdf:type
n8:Vysledek skos:Concept
dcterms:description
Peripheral blood stem cells (PBSCs) are preferred source of hematopoietic stem cells for autologous transplantation. Mobilization of PBSCs using chemotherapy and/or granulocyte colony-stimulating factor (G-CSF) however fails in around 20%. Combining G-CSF with plerixafor increases the mobilizations success. We compared cost-effectiveness of following schemes: the use of plerixafor %22on demand%22 (POD) during the first mobilization in all patients with inadequate response, the remobilization with plerixafor following failure of the first standard mobilization (SSP), and the standard (re)mobilization scheme without plerixafor (SSNP). Decision tree models populated with data from a first-of-a-kind patient registry in six Czech centers (n593) were built to compare clinical benefits and direct costs from the payer's perspective. The success rates and costs for POD, SSP and SSNP mobilizations were; 94.9%, $7,197; 94.7%, $8,049; 84.7%, $5,991, respectively. The direct cost per successfully treated patient was $7,586, $8,501, and $7,077, respectively. The cost of re-mobilization of a poor mobilizer was $5,808 with G-CSF only and $16,755 if plerixafor was added. The total cost of plerixafor %22on-demand%22 in the sub-cohort of poor mobilizers was $17,120. Generally, plerixafor improves the mobilization success by 10% and allows an additional patient to be successfully mobilized for incremental $11,803. Plerixafor is better and cheaper if used %22on demand%22 than within a subsequent remobilization. Peripheral blood stem cells (PBSCs) are preferred source of hematopoietic stem cells for autologous transplantation. Mobilization of PBSCs using chemotherapy and/or granulocyte colony-stimulating factor (G-CSF) however fails in around 20%. Combining G-CSF with plerixafor increases the mobilizations success. We compared cost-effectiveness of following schemes: the use of plerixafor %22on demand%22 (POD) during the first mobilization in all patients with inadequate response, the remobilization with plerixafor following failure of the first standard mobilization (SSP), and the standard (re)mobilization scheme without plerixafor (SSNP). Decision tree models populated with data from a first-of-a-kind patient registry in six Czech centers (n593) were built to compare clinical benefits and direct costs from the payer's perspective. The success rates and costs for POD, SSP and SSNP mobilizations were; 94.9%, $7,197; 94.7%, $8,049; 84.7%, $5,991, respectively. The direct cost per successfully treated patient was $7,586, $8,501, and $7,077, respectively. The cost of re-mobilization of a poor mobilizer was $5,808 with G-CSF only and $16,755 if plerixafor was added. The total cost of plerixafor %22on-demand%22 in the sub-cohort of poor mobilizers was $17,120. Generally, plerixafor improves the mobilization success by 10% and allows an additional patient to be successfully mobilized for incremental $11,803. Plerixafor is better and cheaper if used %22on demand%22 than within a subsequent remobilization.
dcterms:title
Cost-Effectiveness of Hematopoietic Stem Cell Mobilization Strategies Including Plerixafor in Multiple Myeloma and Lymphoma Patients Cost-Effectiveness of Hematopoietic Stem Cell Mobilization Strategies Including Plerixafor in Multiple Myeloma and Lymphoma Patients
skos:prefLabel
Cost-Effectiveness of Hematopoietic Stem Cell Mobilization Strategies Including Plerixafor in Multiple Myeloma and Lymphoma Patients Cost-Effectiveness of Hematopoietic Stem Cell Mobilization Strategies Including Plerixafor in Multiple Myeloma and Lymphoma Patients
skos:notation
RIV/00669806:_____/13:10139964!RIV14-MZ0-00669806
n8:predkladatel
n9:ico%3A00669806
n3:aktivita
n13:I
n3:aktivity
I
n3:cisloPeriodika
6
n3:dodaniDat
n16:2014
n3:domaciTvurceVysledku
n12:7756356
n3:druhVysledku
n10:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n5:predkladatel
n3:idSjednocenehoVysledku
67189
n3:idVysledku
RIV/00669806:_____/13:10139964
n3:jazykVysledku
n6:eng
n3:klicovaSlova
on demand; poor mobilizers; cost-effectiveness; plerixafor; mobilization
n3:klicoveSlovo
n4:cost-effectiveness n4:on%20demand n4:poor%20mobilizers n4:mobilization n4:plerixafor
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[9B76504651D0]
n3:nazevZdroje
Journal of Clinical Apheresis
n3:obor
n14:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
4
n3:rokUplatneniVysledku
n16:2013
n3:svazekPeriodika
28
n3:tvurceVysledku
Vítová, Veronika Kořístek, Zdeněk Lysák, Daniel Tichopád, Aleš
n3:wos
000327782700003
s:issn
0733-2459
s:numberOfPages
9
n18:doi
10.1002/jca.21290